Stock FLGT FULGENT GENETICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Fulgent Genetics, Inc.

Equities

FLGT

US3596641098

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
21.75 USD -0.18% Intraday chart for Fulgent Genetics, Inc. +1.16% -24.77%
05-03 Transcript : Fulgent Genetics, Inc., Q1 2024 Earnings Call, May 03, 2024
05-03 Earnings Flash (FLGT) FULGENT GENETICS Posts Q1 Revenue $64.5M MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Earnings Flash (FLGT) FULGENT GENETICS Posts Q1 Revenue $64.5M
MT
Fulgent Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Year 2024
CI
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022.
CI
Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024
CI
Fulgent Genetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Earnings Flash (FLGT) FULGENT GENETICS Reports Q4 Revenue $70.5M
MT
Earnings Flash (FLGT) FULGENT GENETICS Reports Q4 EPS $0.28
MT
Cooper Unit, Fulgent Genetic to Offer Newborn Genetic Screening Panels
MT
Cord Blood Registry by CooperSurgical, Inc. and Fulgent Genetics, Inc. Launch Innovative Genetic Testing
CI
Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting
CI
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022.
CI
Fulgent Genetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2023
CI
Fulgent Genetics Swings to Loss in Q2, Revenue Declines; Raises Guidance; Shares Surge 10% Pre-Bell
MT
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022.
CI
Fulgent Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023
CI
Fulgent Genetics, Inc. Announces Data from a Phase 1/1b Clinical Study of FID-007 in Treating Various Solid Tancers
CI
Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FLGT Stock
  4. News Fulgent Genetics, Inc.
  5. Highlights